CIK 0001841387 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Candel Therapeutics, Inc.
Sign in to watch- Ticker
- CADL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 522214851
- Phone
- 617-916-5445
- Business address
- 117 KENDRICK STREET, SUITE 450, NEEDHAM, MA, 02494
- 5/A Insider Annual Insider Trading Report
- 5 Insider Annual Insider Trading Report
- SC 13G Stake Amended Statement of Ownership
- SC 13D Stake Beneficial Ownership Report
- 5 Insider Annual Insider Trading Report
- SC 13G Stake Amended Statement of Ownership
- 8-K Event Other events
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 8-K Event Executive or director change
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 8-K Event Other events
- 4/A Open-market buy Director bought 1,625,000 shares at $8.00 ($13,000,000)
- 4 Open-market buy Director bought 125,000 shares at $8.00 ($1,000,000)
- 4 Conversion Chief Scientific Officer acquired 162,137 shares (conversion)
- 4 Open-market buy Director bought 10,000 shares at $8.00 ($80,000)
- 4 Open-market buy Chief Executive Officer bought 25,000 shares at $8.00 ($200,000)
Page 19 of 22 · 422 filings